Works matching DE "IDARUBICIN"

Results: 173
    1
    2
    3
    4
    5
    6

    Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia

    Published in:
    Hematological Oncology, 2020, v. 38, n. 5, p. 754, doi. 10.1002/hon.2806
    By:
    • Borlenghi, Erika;
    • Cattaneo, Chiara;
    • Cerqui, Elisa;
    • Archetti, Silvana;
    • Bertoli, Diego;
    • Bellotti, Daniela;
    • Gramegna, Doriana;
    • Soverini, Giulia;
    • Oberti, Margherita;
    • Schieppati, Francesca;
    • Pagani, Chiara;
    • Passi, Angela;
    • Sciumé, Margherita;
    • Farina, Mirko;
    • Carbone, Cecilia;
    • Crippa, Claudia;
    • Dalceggio, Daniela;
    • Tucci, Alessandra;
    • Rossi, Giuseppe
    Publication type:
    Article
    7

    Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial.

    Published in:
    Hematological Oncology, 2020, v. 38, n. 4, p. 531, doi. 10.1002/hon.2755
    By:
    • Zhou, Xinping;
    • Mei, Chen;
    • Zhang, Jin;
    • Lu, Ying;
    • Lan, Jianping;
    • Lin, Shengyun;
    • Zhang, Yuefeng;
    • Kuang, Yuemin;
    • Ren, Yanling;
    • Ma, Liya;
    • Wei, Juying;
    • Ye, Li;
    • Xu, Weilai;
    • Li, Kongfei;
    • Lu, Chenxi;
    • Jin, Jie;
    • Tong, Hongyan
    Publication type:
    Article
    8
    9
    10
    11
    12

    Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

    Published in:
    Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00369
    By:
    • Boddu, Prajwal;
    • Borthakur, Gautam;
    • Koneru, Mythili;
    • Huang, Xuelin;
    • Naqvi, Kiran;
    • Wierda, William;
    • Bose, Prithviraj;
    • Jabbour, Elias;
    • Estrov, Zeev;
    • Burger, Jan;
    • Alvarado, Yesid;
    • Dekmush, April;
    • Patel, Ami;
    • Cavazos, Antonio;
    • Han, Lina;
    • Cortes, Jorge E.;
    • Kantarjian, Hagop;
    • Andreeff, Michael;
    • Konopleva, Marina
    Publication type:
    Article
    13
    14

    Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial.

    Published in:
    PLoS ONE, 2014, v. 9, n. 10, p. 1, doi. 10.1371/journal.pone.0108107
    By:
    • Masurekar, Ashish Narayan;
    • Parker, Catriona A.;
    • Shanyinde, Milensu;
    • Moorman, Anthony V.;
    • Hancock, Jeremy P.;
    • Sutton, Rosemary;
    • Ancliff, Philip J.;
    • Morgan, Mary;
    • Goulden, Nicholas J.;
    • Fraser, Chris;
    • Hoogerbrugge, Peter M.;
    • Revesz, Tamas;
    • Darbyshire, Philip J.;
    • Krishnan, Shekhar;
    • Love, Sharon B.;
    • Saha, Vaskar
    Publication type:
    Article
    15
    16
    17

    Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

    Published in:
    2019
    By:
    • Boddu, Prajwal C.;
    • Kadia, Tapan M.;
    • Garcia‐Manero, Guillermo;
    • Cortes, Jorge;
    • Alfayez, Mansour;
    • Borthakur, Gautam;
    • Konopleva, Marina;
    • Jabbour, Elias J.;
    • Daver, Naval G.;
    • DiNardo, Courtney D.;
    • Naqvi, Kiran;
    • Yilmaz, Musa;
    • Short, Nicholas J.;
    • Pierce, Sherry;
    • Kantarjian, Hagop M.;
    • Ravandi, Farhad;
    • Garcia-Manero, Guillermo;
    • Kantarjian, Hagop
    Publication type:
    journal article
    18
    19

    A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

    Published in:
    2017
    By:
    • Jabbour, Elias;
    • Short, Nicholas J.;
    • Ravandi, Farhad;
    • Huang, Xuelin;
    • Xiao, Lianchun;
    • Garcia‐Manero, Guillermo;
    • Plunkett, William;
    • Gandhi, Varsha;
    • Sasaki, Koji;
    • Pemmaraju, Naveen;
    • Daver, Naval G.;
    • Borthakur, Gautam;
    • Jain, Nitin;
    • Konopleva, Marina;
    • Estrov, Zeev;
    • Kadia, Tapan M.;
    • Wierda, William G.;
    • DiNardo, Courtney D.;
    • Brandt, Mark;
    • O'Brien, Susan M.
    Publication type:
    journal article
    20

    Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

    Published in:
    2017
    By:
    • Ravandi, Farhad;
    • Jorgensen, Jeffrey;
    • Borthakur, Gautam;
    • Jabbour, Elias;
    • Kadia, Tapan;
    • Pierce, Sherry;
    • Brandt, Mark;
    • Wang, Sa;
    • Konoplev, Sergej;
    • Wang, Xuemei;
    • Huang, Xuelin;
    • Daver, Naval;
    • DiNardo, Courtney;
    • Andreeff, Michael;
    • Konopleva, Marina;
    • Estrov, Zeev;
    • Garcia‐Manero, Guillermo;
    • Cortes, Jorge;
    • Kantarjian, Hagop;
    • Garcia-Manero, Guillermo
    Publication type:
    journal article
    21
    22
    23
    24
    25
    26

    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 535, doi. 10.1111/bjh.18193
    By:
    • Adès, Lionel;
    • Duployez, Nicolas;
    • Guerci‐Bresler, Agnes;
    • Laribi, Kamel;
    • Peterlin, Pierre;
    • Vey, Norbert;
    • Thepot, Sylvain;
    • Wickenhauser, Stefan;
    • Zerazhi, Hacene;
    • Stamatoullas, Aspassia;
    • Wattel, Eric;
    • Recher, Christian;
    • Toma, Andrea;
    • Dimicoli‐Salazar, Sophie;
    • Braun, Thorsten;
    • Beyne‐Rauzy, Odile;
    • Marolleau, Jean‐Pierre;
    • Cheze, Stéphane;
    • Park, Sophie;
    • Cluzeau, Thomas
    Publication type:
    Article
    27
    28

    Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 10, p. 2695, doi. 10.1007/s00277-023-05400-5
    By:
    • Duan, Wenbing;
    • Yang, Sen;
    • Zhao, Ting;
    • Hu, Lijuan;
    • Qin, Yazhen;
    • Jia, Jinsong;
    • Wang, Jing;
    • Lu, Shengye;
    • Jiang, Hao;
    • Zhang, Xiaohui;
    • Xu, Lanping;
    • Wang, Yu;
    • Lai, Yueyun;
    • Shi, Hongxia;
    • Huang, Xiaojun;
    • Jiang, Qian
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.

    Published in:
    Pediatrics International, 2017, v. 59, n. 10, p. 1046, doi. 10.1111/ped.13378
    By:
    • Nakayama, Hideki;
    • Tomizawa, Daisuke;
    • Tanaka, Shiro;
    • Iwamoto, Shotaro;
    • Shimada, Akira;
    • Saito, Akiko M;
    • Yamashita, Yuka;
    • Moritake, Hiroshi;
    • Terui, Kiminori;
    • Taga, Takashi;
    • Matsuo, Hidemasa;
    • Kosaka, Yoshiyuki;
    • Koh, Katsuyoshi;
    • Hosoi, Hajime;
    • Kurosawa, Hidemitsu;
    • Isoyama, Keiichi;
    • Horibe, Keizo;
    • Mizutani, Shuki;
    • Adachi, Souichi
    Publication type:
    Article
    45
    46
    47
    48

    Stroke Alert.

    Published in:
    Neurology Alert, 2017, v. 37, n. 2, p. 14
    By:
    • Fink, Matthew E.
    Publication type:
    Article
    49
    50